We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

OLN:NYSEOlin Corporation Analysis

Data as of 2026-04-22 - not real-time

$26.29

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Olin (OLN) is trading at $26.29, well above its DCF fair value of $18.46, indicating an overvalued position despite a bullish 20‑day SMA (28.38) above the 50‑day SMA (26.25). The stock shows a bullish trend direction but the MACD histogram is negative and the MACD line sits below its signal line, signaling short‑term momentum weakness. Volume is decreasing and volatility is high at 64.7% over the past 30 days, while beta of 1.40 suggests the stock moves more aggressively than the market. Fundamentals are strained: revenue is flat, gross margin is only 7.4%, operating margin is negative, and ROE is –5.2%, with a debt‑to‑equity ratio of 168 indicating heavy leverage. Recent news highlights a Wells Fargo upgrade to Overweight and a $35 price target, but analyst consensus still projects a lower average target near $24, reflecting uncertainty about margin recovery.
Investors should weigh the upside from cost‑saving initiatives and supply‑chain constraints against the valuation premium, high volatility, and debt load. The stock may be suitable for medium‑term positioning if the cost‑cutting program materializes, but caution is warranted given the overvalued price and weak earnings profile.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD histogram and signal line divergence
  • High 30‑day volatility and decreasing volume
  • Proximity to technical support at $25.93

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Wells Fargo Overweight upgrade and $35 price target
  • Projected $100‑$120 million cost‑saving program
  • Supply‑chain constraints favoring U.S. chemical producers

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Significant debt load and low ROE
  • Valuation premium relative to DCF fair value
  • Absence of dividend and cyclic exposure to basic‑materials market

Key Metrics & Analysis

Financial Health

Revenue Growth-0.40%
Profit Margin-1.48%
P/E Ratio29.4
ROE-5.15%
ROA1.12%
Debt/Equity167.83
P/B Ratio1.6
Op. Cash Flow$474.2M
Free Cash Flow$373.0M

Technical Analysis

TrendBullish
RSI45.1
Support$25.93
Resistance$30.46
MA 20$28.38
MA 50$26.25
MA 200$23.15
MACDBearish
VolumeDecreasing
Fear & Greed Index87

Valuation

Fair Value$18.46
Target Price$26.79
Upside/Downside1.89%
GradeOvervalued
TypeValue

Risk Assessment

Beta1.40
Volatility64.75%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.